21:59 , Jul 11, 2019 |  BC Innovations  |  Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
21:04 , Jan 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Autoimmune In vitro , cell culture and mouse studies identified a cyclopeptide STING antagonist that could help treat autoimmune disease. In vitro screening of a small molecule library in mouse and human fibroblast-based functional...
03:21 , Nov 17, 2018 |  BioCentury  |  Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
00:33 , Oct 13, 2017 |  BC Week In Review  |  Clinical News

MeMed test distinguishes between bacterial and viral infections

Data published in Pediatrics from the double-blind, Swiss and Israeli PATHFINDER validation study showed that the ImmunoXpert test from MeMed Diagnostics Ltd. (Tirat Carmel, Israel) was able to successfully distinguish between bacterial and viral infections...
20:49 , Apr 27, 2017 |  BC Extra  |  Company News

AZ returns asthma candidate's rights to Synairgen

Synairgen plc (LSE:SNG) lost 12.75p (49%) to 13.25p on Thursday after it said AstraZeneca plc (LSE:AZN; NYSE:AZN) is returning rights to AZD9412 (SNG001), an inhaled interferon (IFN) beta that was studied to treat asthma. The...
07:00 , May 16, 2016 |  BC Week In Review  |  Clinical News

Emixustat: Phase II started

Acucela began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate once-daily oral emixustat for 12 weeks in 20 patients. Doses of emixustat will be doubled each week until week 4, after which patients will...
08:00 , Nov 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Cyclooxygenase-1 (COX-1); COX-2

Cancer INDICATION: Cancer Patient sample and mouse studies combining COX-1 and/or COX-2 inhibitors with immunotherapies could help treat cancer. In tumor samples from patients with cutaneous melanoma, levels of COX-2 mRNA correlated positively with levels...
07:00 , May 8, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease; multiple sclerosis (MS) Chemokine CXC motif ligand 11 (CXCL11) Mouse studies suggest low doses of CXCL11 could be useful for treating autoimmune...
07:00 , Mar 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease Chemokine CXC motif ligand 10 (CXCL10; IP-10); CXC chemokine receptor 3 (CXCR3) Human sample and mouse studies suggest inhibiting CXCL10 could help...
01:41 , Feb 19, 2014 |  BC Extra  |  Financial News

Novimmune raises CHF60 million

Novimmune S.A. (Plan-les-Ouates, Switzerland) raised CHF60 million ($67.3 million) in an extension of a series B round led by new investor Rosetta Capital. Undisclosed new and existing investors also participated in the extension. Including the...